Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 9/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | SORD | Q00796 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31741465 | 0.83 | KLKB1 (0.61) | KLKB1KDM4E | |
| SCHEMBL21736661 | 0.83 | KLKB1 (0.61) | KLKB1KDM4E | |
| SCHEMBL21736663 | 0.82 | NR1H2 (0.44) | KLKB1KDM4ENR1H2SORD | |
| SCHEMBL21736657 | 0.79 | KLKB1 (0.58) | KLKB1KDM4ENR1H2 | |
| SCHEMBL23769356 | 0.74 | KLKB1 (0.43) | KLKB1KDM4EL3MBTL1 | |
| SCHEMBL31741498 | 0.72 | KLKB1 (1.00) | KLKB1 | |
| SCHEMBL21736743 | 0.70 | KLKB1 (0.49) | KLKB1 | |
| SCHEMBL21736662 | 0.68 | KLKB1 (0.47) | KLKB1 | |
| SCHEMBL20541008 | 0.68 | NR1H2 (0.45) | KLKB1KDM4ENR1H2 | |
| SCHEMBL21736645 | 0.65 | NR1H2 (0.45) | KLKB1KDM4ENR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695334-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | KLKB1 1/4885KDM4E 337/4885L3MBTL1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.